Novartis (NYSE: NVS) is in advanced discussions to acquire Avidity Biosciences (NASDAQ: RNA), Bloomberg News reported Sunday, citing a person with knowledge of the negotiations.
The Swiss pharmaceutical company is said to be preparing an offer exceeding $70 per share for the U.S.-based biotech firm.
https://seekingalpha.com/news/4508452-novartis-is-said-to-near-acquisition-of-avidity-biosciences-for-more-than-70-a-share?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news